Delivery Solutions for Immune Cells to Enable and Advance Cell-Based Therapy
Presented by Sean Chang, Ph.D, Cell Biology Research and Development Scientist, Thermo Fisher Scientific
Date: Saturday, May 5, 2018
Presentation: 10:00 – 10:45 am
Genetic manipulation of blood cells is key to understanding and developing treatments for a broad range of diseases such as cancers and autoimmune diseases. However, the difficulty of delivering molecules into these cells has been an obstacle to more rapid advancement. Here we present viral and non-viral delivery solutions for immune cells.
The Gibco LV-MAX Lentiviral Production System is the first system that provides a scalable and high-yield lentiviral vector production on a serum-free suspension platform, which facilitates the research from bench to clinic. Additionally, the Invitrogen Neon Transfection System offers non-viral delivery of DNA, RNA, and protein efficiently into a variety of blood cells, including human primary T cells, and achieves more than 90% knockout efficiency with CRISPR/Cas9 RNP delivery. More importantly, Neon provides highly efficient CRISPR/Cas9 gene knock-in with our newly developed all-in-one electroporation method, which is ideal for next generation cell therapy.